GlaxoSmithKline Pharmaceuticals Limited Delivers Competitive Performance in Q2FY26, EBIDTA Margin Grows By 250 basis points
Mumbai, India - GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced today its financial results for the second quarter ended September 30, 2025. The Company is growing ahead of competition across its key portfolios, and its newly launched Oncology portfolio is off to a strong start. While the quarter saw muted topline growth due to temporary challenges, the Company demonstrated strong profitability with sustained leadership in anti-infectives, dermatology and vaccines.
During the quarter, Revenue from Operations was INR 974 Crores and Profit After Tax (PAT) was INR 255 Crores. EBIDTA margins for the quarter stood at 34.4%, reflecting a growth of 250 bps, driven by improved gross margins and operating leverage. Topline degrowth for the quarter reflects seasonal disruptions, the transitory impact of GST changes and supply chain adjustments. Supply of a few brands in the General Medicines portfolio was impacted due to a fire that occurred at one of the Company’s contract manufacturing operations. The Company is proactively addressing these matters to return to sustained growth in the coming quarters.
During the quarter, the General Medicines portfolio delivered competitive performance, with key promoted brands achieving market share gains and an Evolution Index (EI)* greater than 100 [Source: IQVIA]. The Vaccines business saw market share expansion, driven by strong demand and continued leadership in the self-pay private market for Paediatric vaccines. The Adult vaccines business continues to see strong traction, led by the growing adoption of Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted), even as GSK remains focused on advancing adult immunisation in India.
GSK’s entry into Oncology with the launch of its specialised therapies Jemperli (Dostarlimab) and Zejula (Niraparib) have been well-received by Healthcare Professionals (HCPs). Together, these assets reinforce the Company’s commitment to bridging critical gaps in specialised cancer care in India.
Bhushan Akshikar, Managing Director, GSK India, said: "Within two months of launch, our Oncology portfolio is impacting patients by addressing a critical unmet need in gynaecological cancers in India. Together, these assets represent meaningful progress in women’s cancer care. Moving ahead, we remain focused on ensuring that cutting-edge innovative treatments are both available and accessible to those who need them the most, supported by our comprehensive patient support and financing initiatives."
Jemperli (dostarlimab) is an immuno-oncology treatment for second-line dMMR endometrial cancer and Zejula (niraparib), is a PARP inhibitor indicated for advanced and recurrent ovarian cancer.
About GSK India: GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a science-led global healthcare company with a purpose to unite science, technology, and talent to get ahead of disease together. For more information, visit GSK-India.com.
Media Contact: Communications and Government Affairs
Carson Dalton - carson.a.dalton@gsk.com
Farah Bookwala - farah.a.bookwala@gsk.com
*The Evolution Index (EI) is a metric used to evaluate the performance of a product relative to the overall market growth.
